Our Mission
Immunogenik is a clinical-stage biotechnology company pioneering next-generation cancer immunotherapies designed to target tumor and reprogram the immune system and overcome resistance in aggressive solid tumors. Supported by multiple non-dilutive government awards, the company is advancing a strong intellectual property portfolio spanning CAR T-cell, antibody, and immune-modulating platforms. At Immunogenik, our mission is to develop and translate innovative immunotherapy approaches that bring meaningful benefit to cancer patients. Our interdisciplinary team of scientists, clinicians, and entrepreneurs collaborates with leading institutions, including the NIH, the University of Florida, and strategic partners such as HITLAB, to accelerate the journey from discovery to patient impact. United by a shared purpose, we are dedicated to transforming the future of cancer treatment through scientific innovation and collaboration.

Governance & Compliance
Immunogenik is committed to operating with the highest standards of governance, compliance, and risk management. We are proactively building the infrastructure, from corporate governance to regulatory readiness and insurance protections, to responsibly advance our science and clinical development programs.
‍